A preclinical study of a novel dual-modality contrast agent in rodent models

• DOI: 10.3389/fbioe.2025.1557772
• Publication Date: 2025-03-20T10:01:29Z
• Authors: Xuelai Zhou; Kangli Jiang; Yuxin Han; Shuxu Yang
• Keywords: Indocyanine Green; Brain tumor; Modality (human–computer interaction); Imaging agent

Introduction Glioblastoma (GBM) represents the most aggressive and prevalent form of primary malignant brain tumor in adults, with surgical intervention being treatment modality. To enhance outcomes extend patient survival, we have engineered a dual-modality MRI/FI contrast agent known as PL002 to aid management GBM. Methods In this study, an orthotopic glioma model was established mice via intracranial injection U-87 MG cells. Subsequently, animals were intravenously injected placed 7.0T magnetic resonance imaging (MRI) device evaluate effects. After MRI scan, fluorescence techniques employed observe distribution at both tissue cellular levels. Moreover, healthy rat models utilized investigate pharmacokinetic characteristics, distribution, safety profile PL002. Results The molecular structure contains gadolinium (Gd 3+ ) indocyanine green (ICG), demonstrating optimal effects within dosage range 10-50 mg/kg, half-life 2.51 4.87 hours. Even relatively low concentrations brain, can provide stable sustained support for up 72 No abnormalities observed rats 100 mg/kg. Discussion Compared Gadavist® ICG, provided FI GBM h, broad therapeutic window. This holds significant potential promise applications preoperative assessment resection margins, real-time intraoperative guidance, postoperative verification extent resection.